この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2010/1/131 分で読めます
Prospective Grant of Exclusive License: Development of V-ATPase Inhibitor Compounds for the Treatment of Human Cancers and Osteoclastic Bone Diseases Excluding Rheumatoid Arthritis and Other Osteo-Specific Auto-Immune Diseases
ローカル自動翻訳 · 情報源の原言語
概要
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to the Australian Institute of Marine Science ("AIMS") located in Townsville, Queensland, Australia.
情報源の原言語: Federal Register — Health and Human Services原文の発表を開く →